@azog1993 @jimeekay @Debunk_the_Funk @BretWeinstein Oh, you mean they used a completely safe method that is superior at determining non-inferiority? https://t.co/frQOYL8lNS https://t.co/k3HieMbVr2
@PeaceLillie33 @MinorityView @thatsnotmine125 @CervenkaTrevin Most initial vaccines WERE tested against saline placebos. Including the Covid vaccine. It's simple logic. If A(placebo) < B (vax1) and C (vax2) >= B then C >= A. It's called non-infe
@PeaceLillie33 @thatsnotmine125 @CervenkaTrevin Is testing against the currently best available vaccine not good enough? Why not? Many initial versions of vaccines, such as the Covid vaccine, WERE tested against a placebo. Placebo's are not needed after in
RT @vipuljairath: Renewed interest in our field in non-inferiority trials. These have a role in specific circumstances and have nuances in…
RT @vipuljairath: Renewed interest in our field in non-inferiority trials. These have a role in specific circumstances and have nuances in…
Renewed interest in our field in non-inferiority trials. These have a role in specific circumstances and have nuances in their design, conduct and interpretation. This is by far one of the best reviews written about these trials. https://t.co/KeKFmx8LsW
@LoofboroDan @Thomas_Banacek @zookeepermc @jonathanstea But my answer, which you never responded to, was not: https://t.co/pPHdl10qOO
@LoofboroDan @jonathanstea With existing vaccines, it is completely logically unnecessary when testing non-inferiority in addition to observational studies are just as good. Uses of observational studies: https://t.co/1Ipx652oUd Understanding non-inferiori
@Gish19382 @Fynnderella1 I literally posted scientific literature explaining the logic and value behind testing against an existing treatment to determine efficacy: https://t.co/k3HieMbVr2 Here is one on observational studies: https://t.co/1Ipx652oUd Will
@Gish19382 @Fynnderella1 It's called testing "non-inferiority" and it is a standard practice in empirical research: https://t.co/k3HieMbVr2 https://t.co/MUT0pUSiDA https://t.co/e93iGldQgv
@Gopal_Kot This happens often - this review addresses it nicely: https://t.co/xDYPKwyQPy
RT @MarionKCampbell: The following paper from the Trials journal also outlines many of the key issues with non-inferiority trials 7/8 https…
RT @MarionKCampbell: The following paper from the Trials journal also outlines many of the key issues with non-inferiority trials 7/8 https…
RT @MarionKCampbell: The following paper from the Trials journal also outlines many of the key issues with non-inferiority trials 7/8 https…
The following paper from the Trials journal also outlines many of the key issues with non-inferiority trials 7/8 https://t.co/PGjBHgU90i https://t.co/TTk8Pc15lA
T1c: Both trials were RCTs designed to test the non-inferiority of apixaban vs. standard VKAs. #NephJC https://t.co/iPVuzfxCvi https://t.co/4RcScngBTn
RT @haus_ppl: If I ever teach a trials class, I know what trial I'll use as an example. https://t.co/mcP0WqHWay @CPita3 @sameo416 @Mark_…
RT @haus_ppl: If I ever teach a trials class, I know what trial I'll use as an example. https://t.co/mcP0WqHWay @CPita3 @sameo416 @Mark_…
RT @haus_ppl: If I ever teach a trials class, I know what trial I'll use as an example. https://t.co/mcP0WqHWay @CPita3 @sameo416 @Mark_…
If I ever teach a trials class, I know what trial I'll use as an example. https://t.co/mcP0WqHWay @CPita3 @sameo416 @Mark_Ungrin @ToshiAkima @FinchTH https://t.co/0gMqixT36H
@MIGO_Offiziell Das Paper hilft beim verstehen von Superiority vs Non-Inferiority vs Equivalence https://t.co/kiH7Bf6RnN
@afif_elKhuffash @natetexsun @EBNEO @AAPneonatal Image taken from - https://t.co/OmZ7ZduDWL
تفضلو ٣ مصادر مفيده فيها كل التفاصيل عن Non-inferiority trials #clinicalresearch ↪️ https://t.co/D39EBOdLnc https://t.co/sPrqoofEOF https://t.co/aP0SHQ5Bbt
RT @JeffFreiberg: @BrainOfBPharm @BradSpellberg @ABsteward @DrToddLee I want to make sure to give credit to the paper the figure comes from…
RT @JeffFreiberg: @BrainOfBPharm @BradSpellberg @ABsteward @DrToddLee I want to make sure to give credit to the paper the figure comes from…
@BrainOfBPharm @BradSpellberg @ABsteward @DrToddLee I want to make sure to give credit to the paper the figure comes from https://t.co/nmjx4787xz
@bjcohenmd @kaulcsmc Agree although #Noninferiority trials can also demonstrate superiority (sequential testing). #RELY led by #StuartConnolly (who nurtured my love for methods) is an example, many others too. Figure below shows possible outcomes in NI tr
@kaulcsmc @VictorDayan1 @drjohnm @theheartorg Can't inferiority of PCI, hence, superiority of CABG be interpreted from the CI as is? The highlighted text talks about testing for superiority of the case, not the control, but doesn't the same apply for inf
@First10EM The ask for equivalence trials is way harder than you suggest in that tweet Seriously suggest you check out that link to the blog we wrote or perhaps this review https://t.co/kb1cJpq5AP
Through the looking glass: understanding non-inferiority | Trials | Full Text https://t.co/4FvdQPgLI6
生物統計の論文探ししてたはずが、イントロが「...とアリスは言いました」で論文じゃないページを開いてしまったかと思ったら普通にレビュー論文だった こういうイントロもあるんですね https://t.co/y6yFzhNlJy
RT @vipuljairath: This is still one of my favourite reviews. A primer which demystifies equivalence, non-inferiority and superiority- and c…
This is still one of my favourite reviews. A primer which demystifies equivalence, non-inferiority and superiority- and considerations for choosing the margin for NI/equivalence. Accessed 139K times for good reason! https://t.co/q5qKWhcZkc
@nbamat @oelkhateeb @BrianKingNeo @johansson247 @JAMAPediatrics @EBNEO “NOT non-inferior” is a confusing term - I’m not sure if this term is standard at all NEJM paper https://t.co/PNWUC5qpxj doesn’t use this term whereas the other EBM paper & some
@dr_benoy_n_shah @lamelaspablo @ISeropianMD @DVervoort94 @rachkataria @drkirmani @DocStrom @JonathanWHinton @sarahhudsonuk @kaschenke @RodrigogpLima @BirkhoelzerS @GilbertTangMD @vass_vassiliou @kaulcsmc “Not non inferior” may or may not be “inferior”. H
Interesante...para entender mejor los estudios de no inferioridad 👉 https://t.co/lmGj8g4mjO https://t.co/Ams0q9FX0o
RT @hswapnil: @ssfarouk Source: https://t.co/kb1cJpq5AP #NephJc
@ssfarouk Source: https://t.co/kb1cJpq5AP #NephJc
@CharlieTomson @OttawaRenal @manasib33 See this image from https://t.co/sWCIech2Vp to see where KOMPAS results lie on the N spectrum 16/ https://t.co/4hLElXGlVG
"Analysis not done by intention to treat." That is an important analysis when looking at superiority trials but is not a valid argument with non-inferiority trials. https://t.co/KCerMd9yZV
@DrOzanDemir "E" is surely wrong there. Does "E" really look inferior to you? Compare to this much clearer figure from this paper: https://t.co/lMMOzBVEsX https://t.co/cjf24BCmL5
@krychtiukmd Hi @DrOzanDemir @estherb54 @ottoecho @rincondesisifo @DrRaniKhatib! Would you consider deleting your tweets on the BMJ Heart non-inferiority paper? Take a close look at the main figure. Does it *really* make sense to you? Compare it to the
@bogdienache Indeed @krychtiukmd please just delete the tweet Figure is wrong in original paper See a much better review & description here https://t.co/t0RzzCphxg
RT @MartinFierro769: @ProfDFrancis 9/n Mais ce sera plus facile à comprendre avec un dessin et j'en ai trouvé un ici https://t.co/J2ggHbLzb…
@ProfDFrancis 9/n Mais ce sera plus facile à comprendre avec un dessin et j'en ai trouvé un ici https://t.co/J2ggHbLzbo . J'ai entouré le cas où un médicament est à la fois non inférieur et inférieur pour le guide CONSORT https://t.co/fI91tyM7aZ
@ajumathew_ @VPrasadMDMPH @venkymd @drnirmalraut @venkmurthy @THilalMD Swapnil @hswapnil commented on this on twitter 'Through the looking glass: understanding non-inferiority' https://t.co/VFezQiZfKc https://t.co/V01PMkjaCq
Hence forth in any twitter argument I shall be using the standards on non inferiority trials logic. Am I “ not unacceptably worse.” In my argument 😂 😂 😂 Through the looking glass: understanding non-inferiority https://t.co/NJCMsPzYQl https://t.co/CBiBHA
@CombatSportPhys Plus the explanations in various papers just get better 😂 Through the looking glass: understanding non-inferiority https://t.co/NJCMsPzYQl https://t.co/pXQGWuXf1z
@drbretty @talcroft Some links here that you may find useful @talcroft https://t.co/cKnthtkAz9 https://t.co/KxODqEqjjE
On PIVOTAL which was a non-inferiority trial Aka an excuse for me to show this figure from https://t.co/30MGROJI6j #CSNAGM https://t.co/SsRL54Btcy
@SwastiThinks @Nephro_Sparks this is good I like this #OpenAccess review as well: https://t.co/uEBHVQ76k1 https://t.co/SOaFZTEWvi
@ADAlthousePhD @anish_koka @MasriAhmadMD @michelaccad @KBerlacher Agree with Andrew. NI makes perfect sense here You can quibble about the NI margin (1%) - how did they decide that? That’s always the contentious part.. See https://t.co/uEBHVQ76k1 https://t
RT @NephJC: T2j: Non-inferior and superior is not a paradox, see https://t.co/XgbiA801vh for more; will be first option in figure below #Ne…
RT @NephJC: T2j: Non-inferior and superior is not a paradox, see https://t.co/XgbiA801vh for more; will be first option in figure below #Ne…
RT @NephJC: T2j: Non-inferior and superior is not a paradox, see https://t.co/XgbiA801vh for more; will be first option in figure below #Ne…
T2j: Non-inferior and superior is not a paradox, see https://t.co/XgbiA801vh for more; will be first option in figure below #NephJC https://t.co/tlXKjUkrOP
RT @hswapnil: @DrDanMO @nephron_andon @NephJC Source: https://t.co/uEBHVQ76k1 Excellent review #NephJc
RT @hswapnil: @DrDanMO @nephron_andon @NephJC Source: https://t.co/uEBHVQ76k1 Excellent review #NephJc
@DrDanMO @nephron_andon @NephJC Source: https://t.co/uEBHVQ76k1 Excellent review #NephJc
#NephJC tonight is a non-inferiority trial People make a lot of foolish comments about NI trials Don't be like those people Read this paper for background: https://t.co/uEBHVQ76k1
@AnilMakam @ethanjweiss A NI of 30% doesn’t imply RR of 1.3 It’s the upper bound Usually RR will need to be far lower to satisfy NI See from https://t.co/30MGROJI6j and also..2/3 https://t.co/VCstvUxJIh
@jddneary @BenMazer @JeremySussman @VPrasadMDMPH See https://t.co/30MGROJI6j I posit than fewer needles is a desirable thing with newer drugs (Maybe patients would too?) Suspect severe hypoglycaemia also much less with non-insulin/non-SU drugs, but har
RT @hswapnil: @VinayPrasad82 @medevidenceblog Mostly issue with large margins? Allows mischief in this area (figure from https://t.co/uEBHV…
The single most important thing to understand about this study is that it did *not* prove cricoid pressure doesn't work. Not just me saying that; it's the authors! The double-negative and inverted hypotheses of non-inferiority has confused a lot of people!
@EpiEllie @anish_koka @bbrsntd @HeartSisters @raj_mehta @HealthNewsRevu @BettinaRyll sorry this makes zero sense. NI trials have been misused - doesn't mean they are always not in patients interests Recommend https://t.co/uEBHVQ76k1 NI margin refers to *o
A non-inferiority experiment shows:new intervention is not 'inferior' to the previous one or The new intervention is 'not unacceptably worse' than the intervention used as the control #Biostat #Epidemiology https://t.co/zVntnrnThZ
RT @hswapnil: For more on non-inferiority see https://t.co/uEBHVQ76k1 & https://t.co/xVuAdz2BEF #ISPD18 https://t.co/Fv09wEScB6
For more on non-inferiority see https://t.co/uEBHVQ76k1 & https://t.co/xVuAdz2BEF #ISPD18 https://t.co/Fv09wEScB6
RT @hswapnil: @ProfDFrancis @Badves More mind benders in this graph from https://t.co/uEBHVQ76k1 https://t.co/klYQTlvQnm
RT @hswapnil: @ProfDFrancis @Badves More mind benders in this graph from https://t.co/uEBHVQ76k1 https://t.co/klYQTlvQnm
@ProfDFrancis @Badves More mind benders in this graph from https://t.co/uEBHVQ76k1 https://t.co/klYQTlvQnm
@kidneybloke @Badves @VladoPerkovic @NEJM Nice! I also like this: https://t.co/uEBHVQ76k1 https://t.co/g9pdFtXesk
RT @hswapnil: @ProfDFrancis Good Explanation from https://t.co/t0RzzC7G8G https://t.co/cmlcH21VwD
RT @hswapnil: @ProfDFrancis Good Explanation from https://t.co/t0RzzC7G8G https://t.co/cmlcH21VwD
@ProfDFrancis Good Explanation from https://t.co/t0RzzC7G8G https://t.co/cmlcH21VwD
@ProfDFrancis I think Figure 2 here gives a good illustration on how a treatment can be inferior and non-inferior at the same time. https://t.co/InqNbygk3i
RT @hswapnil: @VinayPrasad82 @medevidenceblog Mostly issue with large margins? Allows mischief in this area (figure from https://t.co/uEBHV…
RT @hswapnil: @VinayPrasad82 @medevidenceblog Mostly issue with large margins? Allows mischief in this area (figure from https://t.co/uEBHV…
RT @hswapnil: @VinayPrasad82 @medevidenceblog Mostly issue with large margins? Allows mischief in this area (figure from https://t.co/uEBHV…
RT @hswapnil: @VinayPrasad82 @medevidenceblog Mostly issue with large margins? Allows mischief in this area (figure from https://t.co/uEBHV…
@VinayPrasad82 @medevidenceblog Mostly issue with large margins? Allows mischief in this area (figure from https://t.co/uEBHVQ76k1) Though why should NI trials be allowed at all for new drugs is beyond me🤔 https://t.co/FNtto4mpIZ
RT @hswapnil: For more on non-inferiority design see https://t.co/t0RzzCphxg (openaccess) #KidneyWK https://t.co/HMR4SobAsb
@Badves not necessarily in non-inferiority right? PP maybe more robust than ITT from https://t.co/uEBHVQoHIB #KidneyWk https://t.co/yPEqUNVlhv
Was a superiority hypothesis embedded in this trial. https://t.co/fFjWyxYQwa
For more on non-inferiority design see https://t.co/t0RzzCphxg (openaccess) #KidneyWK https://t.co/HMR4SobAsb
RT @hswapnil: @adamcifu Gated! Is it better than this one (#openaccess) https://t.co/uEBHVQoHIB ? https://t.co/OFU4ZZxbRe
@adamcifu Gated! Is it better than this one (#openaccess) https://t.co/uEBHVQoHIB ? https://t.co/OFU4ZZxbRe
RT @hswapnil: @NephJC Ah, 20% non-inferiority (same as RAVE ). Time for me to roll out the non-inferiority must read https://t.co/uEBHVQoHI…
RT @hswapnil: @NephJC Ah, 20% non-inferiority (same as RAVE ). Time for me to roll out the non-inferiority must read https://t.co/uEBHVQoHI…